Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-04447943 + donepezil
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-04447943 + donepezil is a combination of two investigational and approved small molecule drugs. PF-04447943 is a potent and selective inhibitor of phosphodiesterase 9A (PDE9A), which is being investigated for its effect on cognitive functions by enhancing cyclic guanosine monophosphate (cGMP) signaling pathways in the brain. Donepezil is an acetylcholinesterase inhibitor, already approved and widely used to treat symptoms of Alzheimer's disease by increasing acetylcholine concentrations in the brain. This combination is being studied for potential synergistic cognitive benefits in Alzheimer's disease, targeting multiple neurochemical pathways involved in memory and cognition[1][8].
02
Targets
AcetylcholinesterasePDE9A (Phosphodiesterase 9A)
Beyond the preview
Go deeper on PF-04447943 + donepezil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-04447943 + donepezil.